Get the Stockscreener App
2.80
4.44%
-0.13
Savara Inc stock is traded at $2.80, with a volume of 909.98K.
It is down -4.44% in the last 24 hours and down -13.31% over the past month.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
See More
Previous Close:
$2.93
Open:
$2.96
24h Volume:
909.98K
Relative Volume:
0.68
Market Cap:
$480.53M
Revenue:
-
Net Income/Loss:
$-54.70M
P/E Ratio:
-8.4848
EPS:
-0.33
Net Cash Flow:
$-51.36M
1W Performance:
+2.94%
1M Performance:
-13.31%
6M Performance:
-37.36%
1Y Performance:
-36.51%
1-Day Range:
$2.74
$2.96
1-Week Range:
$2.74
$3.135
52-Week Range:
$2.60
$5.70
Savara Inc Stock (SVRA) Company Profile
Name
Savara Inc
Sector
Industry
Phone
51285113796
Address
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
2.80 | 480.53M | 0 | -54.70M | -51.36M | -0.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Nov-13-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-24 | Initiated | JMP Securities | Mkt Outperform |
| Nov-07-23 | Initiated | Guggenheim | Buy |
| May-16-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-31-23 | Downgrade | Jefferies | Buy → Hold |
| Mar-16-21 | Initiated | Piper Sandler | Overweight |
| Mar-15-21 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-13-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-13-19 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-13-18 | Resumed | ROTH Capital | Neutral |
| Jan-03-18 | Initiated | Ladenburg Thalmann | Buy |
| Sep-27-17 | Resumed | ROTH Capital | Buy |
| Sep-22-17 | Initiated | Jefferies | Buy |
| Sep-11-17 | Initiated | JMP Securities | Mkt Outperform |
View All
Savara Inc Stock (SVRA) Latest News
Savara Inc Updates Corporate Presentation in Latest SEC Filing - Defense World
Savara (NASDAQ:SVRA) Stock Price Down 5.3%Here's What Happened - MarketBeat
Savara Inc. Launches Early Access Program for Rare Lung Disease Treatment - MSN
Savara Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference - MSN
Savara (NASDAQ:SVRA) Shares Up 8.1%Should You Buy? - MarketBeat
Barclays PLC Buys 158,244 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Savara Highlights MOLBREEVI’s Potential in Rare Disease Market - TipRanks
Institutional investors may adopt severe steps after Savara Inc.'s (NASDAQ:SVRA) latest 11% drop adds to a year losses - Simply Wall St
Savara Inc (NASDAQ:SVRA) Shares Sold by Jane Street Group LLC - Defense World
SVRA Stock Touches 52-Week Low at $2.81 Amid Market Challenges By Investing.com - Investing.com South Africa
SVRA Stock Touches 52-Week Low at $2.81 Amid Market Challenges - Investing.com Australia
Savara Inc. Grants Inducement Awards to New Employees - MSN
Principal Financial Group Inc. Sells 7,607 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc (NASDAQ:SVRA) Receives $9.86 Average Price Target from Brokerages - Defense World
Savara Inc (NASDAQ:SVRA) Receives $9.86 Consensus Target Price from Analysts - MarketBeat
Geode Capital Management LLC Raises Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World
Geode Capital Management LLC Buys 264,825 Shares of Savara Inc (NASDAQ:SVRA) - MarketBeat
Barclays PLC Increases Stock Position in Savara Inc (NASDAQ:SVRA) - Defense World
Who Really Pulls the Strings at Savara? Discover the Power Players! - Jomfruland.net
Savara Inc. (NASDAQ:SVRA) is largely controlled by institutional shareholders who own 53% of the company - Yahoo Finance
Savara Begins FDA Submission for Rare Lung Disease Treatment - MSN
State Street Corp Acquires 560,242 Shares of Savara Inc (NASDAQ:SVRA) - MarketBeat
State Street Corp Purchases 560,242 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Savara Strengthens Team with Strategic Equity Incentives: 200,000 Shares Awarded to New Hires - StockTitan
Savara (NASDAQ:SVRA) Earns “Market Outperform” Rating from JMP Securities - Defense World
Wells Fargo Initiates Coverage of Savara (SVRA) with Overweight Recommendation - MSN
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 6,141 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Savara: Rolling BLA Submission Of MOLBREEVI Generates Catalysts To Track (NASDAQ:SVRA) - Seeking Alpha
Savara (NASDAQ:SVRA) Earns Overweight Rating from Analysts at Wells Fargo & Company - MarketBeat
Savara's SWOT analysis: rare disease biotech stock poised for growth By Investing.com - Investing.com Australia
Savara's SWOT analysis: rare disease biotech stock poised for growth - Investing.com
Savara (NASDAQ:SVRA) Trading 5.6% HigherTime to Buy? - MarketBeat
BNP Paribas Financial Markets Purchases 18,534 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
JMP Securities Reaffirms "Market Outperform" Rating for Savara (NASDAQ:SVRA) - MarketBeat
Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Business Wire
Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace
Savara's CFO David Lowrance sells $83,277 in stock By Investing.com - Investing.com South Africa
The Manufacturers Life Insurance Company Acquires 3,706 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Savara director Hawkins sells $26,568 in stock By Investing.com - Investing.com Australia
Savara director Hawkins sells $26,568 in stock - Investing.com India
Savara CEO Matthew Pauls sells $180,828 in stock - Investing.com India
Savara's SWOT analysis: molgramostim's promise buoys stock amid challenges - Investing.com
Savara Inc Stock (SVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):